ReviewAnnals of intensive care2016
What's new in multidrug-resistant pathogens in the ICU?
Review in Annals of intensive care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04927806 (The Effectiveness of Antimicrobial Breathing System on the Presence of Multidrug-resistant Organisms), which is not on this map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effectiveness of Antimicrobial Breathing System on the Presence of Multidrug-resistant Organisms
Who cites it
44 citing papers in PubMed.
- Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial.American journal of respiratory and critical care medicine · 2021Trial
- Six Years ofAntibiotics (Basel, Switzerland) · 2026Article
- Incidence of nosocomial infection in the intensive care unit of Ghazi Al-Hariri teaching hospital.Wiener klinische Wochenschrift · 2026Article
- Infections and mortality in ICU patients undergoing continuous renal replacement therapy: a retrospective cohort study.BMC nephrology · 2025Article
- Antibiotic resistance in Helicobacter pylori: a genetic and physiological perspective.Gut pathogens · 2025Review
- Advancing understanding and management of invasive fungal diseases in the intensive care unit: Insights from FUNDICU consensus definitions.Journal of intensive medicine · 2024Article
- The protagonist of contemporary and emerging nanotechnology-based theranostics and therapeutic approaches in reshaping intensive care unit.Saudi medical journal · 2024Review
- Decolonization strategies against multidrug resistant organisms in the ICU.Intensive care medicine · 2024Article
- High Prevalence of Multidrug-Resistant Bacteria in the Trachea of Intensive Care Units Admitted Patients: Evidence from a Bangladeshi Hospital.Antibiotics (Basel, Switzerland) · 2024Article
- Clinical Characteristics and Risk Factors for Infection and Death in Critically Ill Patients with Pulmonary Infection withInfection and drug resistance · 2024Article
- Is there a role for microbiome-based approach in common variable immunodeficiency?Clinical and experimental medicine · 2023Review
- Epidemiology of Resistance Determinants Identified in Meropenem-NonsusceptibleAntimicrobial agents and chemotherapy · 2023Article
- Development of a local antibiogram for a teaching hospital in Ghana.JAC-antimicrobial resistance · 2023Article
- The role of nanotechnology-based approaches for clinical infectious diseases and public health.Frontiers in bioengineering and biotechnology · 2023Review
- Association of Multidrug Resistance Bacteria and Clinical Outcomes of Adult Patients with Sepsis in the Intensive Care Unit.Tropical medicine and infectious disease · 2022Article
- Relationship between Biofilm-Formation, Phenotypic Virulence Factors and Antibiotic Resistance in Environmental Pseudomonas aeruginosaPathogens (Basel, Switzerland) · 2022Article
- A stratification strategy to predict secondary infection in critical illness-induced immune dysfunction: the REALIST score.Annals of intensive care · 2022Article
- Sepsis Management in Southeast Asia: A Review and Clinical Experience.Journal of clinical medicine · 2022Review
- How to improve hospital admission screening for patients at risk of multidrug-resistant organism carriage: a before-and-after interventional study and cost-effectiveness analysis.BMJ open quality · 2022Article
- Understanding decisions about antibiotic prescribing in ICU: an application of the Necessity Concerns Framework.BMJ quality & safety · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last several decades, antibacterial drug use has become widespread with their misuse being an ever-increasing phenomenon. Consequently, antibacterial drugs have become less effective or even ineffective, resulting in a global health security emergency. The prevalence of multidrug-resistant organisms (MDROs) varies widely among regions and countries. The primary aim of antibiotic stewardship programs is to supervise the three most influential factors contributing to the development and transmission of MDROs, namely: (1) appropriate antibiotic prescribing; (2) early detection and prevention of cross-colonization of MDROs; and (3) elimination of reservoirs. In the future, it is expected that a number of countries will experience a rise in MDROs. These infections will be associated with a high consumption of healthcare resources manifested by a prolonged hospital stay and high mortality. As a counteractive strategy, minimization of broad-spectrum antibiotic use and prompt antibiotic administration will aid in reduction of antibiotic resistance. Innovative management approaches include development and implementation of rapid diagnostic tests that will help in both shortening the duration of therapy and allowing early targeted therapy. The institution of more accessible therapeutic drug monitoring will help to optimize drug administration and support a patient-specific approach. Areas where further research is required are investigation into the heterogeneity of critically ill patients and the need for new antibacterial drug development.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.